Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$8.50 USD
-0.41 (-4.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $8.49 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNGX 8.50 -0.41(-4.60%)
Will TNGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNGX
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Other News for TNGX
Buy Rating Affirmed for Tango Therapeutics on Strong PRMT5 Program Progress and Solid Financials
Analyst Expectations For Tango Therapeutics's Future
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Tango Therapeutics price target raised by $2 at Wedbush, here's why
Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)